

**Supplementary Table 1. Demographic, epidemiological, and clinical characteristics**

<b>Variable</b>	<b>Result</b>
<b>Demographics/epidemiological characteristics</b>	
Patients	117
Age (years)	55 (46-64)
Male sex	80 (68.4%)
Obesity	17 (14.5%)
Arterial hypertension	34 (29.1%)
Diabetes mellitus	24 (20.5%)
Ischemic cardiopathy	9 (7.7%)
<b>Chronic hepatitis B characteristics</b>	
Treatment (ETV/TDF)	50 (42.7%) / 67 (57.3%)
Advanced fibrosis (F3-F4)	28 (23.9%)
HBeAg positive	21 (17.9%)
Detectable HBV DNA	22 (18.8%)
Treatment duration (months)	67 (24.5-107)
<b>COVID-19 characteristics</b>	
Management:	
Outpatient	71 (60.7%)
Inpatient (ward)	41 (35%)
Intensive care unit	5 (4.3%)
Severe COVID-19	22 (18.8%)
Oxygen therapy:	
No need	81 (69.2%)
Basic therapy	24 (20.5%)
Ventilatory support	12 (10.3%)
Hospitalization length (days)	16 (5.7- 17.1)
Death	6 (5.1%)

Results expressed as the median (1<sup>st</sup>-3<sup>rd</sup> quartile) and n (%).

ETV, entecavir; TDF, tenofovir; HBV, hepatitis B virus

**Supplementary Table 2. Covariate balance summary**

	Raw	Weighted
Total number of patients	117	117
TDF patients	67	57.6
ETV patients	50	57.4

	Standardized differences		Variance ratio	
	Raw	Weighted	Raw	Weighted
Age	-0.42	0.03	0.69	0.78
Sex	-0.33	-0.04	0.77	0.96
Obesity	-0.35	-0.05	0.48	0.88
Arterial hypertension	-0.57	0.01	0.61	0.99
Diabetes mellitus	-0.48	0.02	0.49	1
HBeAg positive	-0.08	-0.01	0.87	1.03
Advanced fibrosis	-0.36	-0.05	0.66	0.93
Age	-0.42	0.03	0.69	0.78
Sex	-0.33	-0.04	0.77	0.96